Clinical trials: Spondyloarthritis, Axial
Ankylosing Spondylitis
Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis
The purpose of this study is to compare the efficacy of etanercept and sulphasalazine in the treatment of Ankylosing Spondylitis.
- Trial name
- NCT00247962
- Testing
- etanercept, sulphasalazine (SSZ)
- Where
- 83 sites in Australia, Austria and 16 more
- Volunteers
- 566 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Axial Spondyloarthritis, Back Pain
Spondyloarthritis Inception Cohort of Southern Denmark
People with axial spondyloarthritis (axSpA) experience a diagnostic delay of 6.5 years in men and up to 8.8 years in women. One of the reasons for the diagnostic delay seems to be limited awareness of the disease characteristics…
- Trial name
- SPINCODE (NCT06337513)
- Testing
- Rehabilitation intervention, Usual care
- Where
- Denmark
- Volunteers
- 250 people
- Sponsor
- The Danish Center for Expertise in Rheumatology
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases
The goal of this clinical trial is to assess the effectiveness of a disease activity guided dose reduction strategy of Janus kinase inhibitor (JAKi) compared to disease activity guided JAKi continuation in patients with…
- Conditions
- Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Axial Spondyloarthritis (AxSpA)
- Trial name
- REDO-JAK (NCT07160231)
- Testing
- JAKi dose reduction strategy, JAKi disease activity guided continuation of same dose strategy
- Where
- 7 sites in Netherlands
- Volunteers
- 200 people
- Sponsor
- Sint Maartenskliniek
Rheumatoid Arthritis, Ankylosing Spondylitis
Korean College of Rheumatology Biologics and Targeted Therapy Registry
We established a nationwide biologics and targeted synthetic DMARDs registry (in the form of an inception cohort) to study the safety profiles in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- KOBIO (NCT01965132)
- Testing
- Biologic or targeted synthetic DMARD
- Where
- South Korea
- Volunteers
- 10,000 people
- Sponsor
- Seoul National University Hospital
Axial Spondyloarthritis (AxSpA), Spondyloarthritis (SpA)
Multicenter Validation of the 2025 Classification Criteria for Axial Spondyloarthritis
This study aims to validate the 2025 ASAS-SPARTAN revised classification criteria for axial spondyloarthritis (axSpA) in the Chinese population through a multicenter, prospective, cross-sectional observational study.
- Conditions
- Axial Spondyloarthritis (AxSpA), Spondyloarthritis (SpA), Chronic Back Pain
- Trial name
- MVAS2025 (NCT07724847)
- Testing
- Diagnostic Assessment
- Where
- China
- Volunteers
- 247 people
- Sponsor
- Chinese PLA General Hospital
Axial Spondyloarthritis, Ankylosing Spondylitis
axSEND: Exploring Immune and Microbiota Effects of a Partial Enteral Nutrition Diet in Axial Spondyloarthritis
People with axial spondyloarthritis (axSpA) often have intestinal inflammation and intestinal microbiome dysbiosis, with some similarities to Crohn's-like inflammatory bowel disease (IBD) gut inflammation.
- Conditions
- Axial Spondyloarthritis, Ankylosing Spondylitis, Inflammation, Dysbiosis
- Trial name
- axSEND (NCT06460805)
- Testing
- Partial enteral nutrition
- Where
- 2 sites in United Kingdom
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- NHS Greater Glasgow and Clyde
Axial Spondylarthritis (axSpA), Secukinumab
Efficacy and Influencing Factors of Secukinumab in Patients With Axial Spondyloarthritis
This study aimed to explore the efficacy and influencing factors of secukinumab in axSpA patients by conducting a real-world retrospective analysis.
- Trial name
- NCT07130331
- Testing
- Secikinumab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Giant Cell Arteritis (GCA), Spondylarthritis
Study of the Association Between Sacroiliitis/Axial Spondylarthritis and Giant Cell Arteritis/ Polymyalgia Rheumatica
The purpose of the study is to recruit as many patients as possible presenting with sacroiliitis or authentic axial spondylarthritis and giant cell arteritis.
- Conditions
- Giant Cell Arteritis (GCA), Spondylarthritis, Polymyalgia Rheumatica
- Trial name
- SAGE PPR (NCT07394478)
- Testing
- Description of population
- Where
- 2 sites in France
- Volunteers
- 10 people
- Sponsor
- Hôpital NOVO
Crohn Disease, Ulcerative Colitis
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
The aim of the study is to describe the real-world profile of patients treated with adalimumab FK in gastroenterology, dermatology or rheumatology in order to evaluate in this population the predictive factors of therapeutic…
- Conditions
- Crohn Disease, Ulcerative Colitis, Psoriasis, Ankylosing Spondylitis
- Trial name
- OPALE (NCT05051943)
- Where
- France
- Volunteers
- 754 people
- Sponsor
- Fresenius Kabi
Spondylitis, Ankylosing
Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
This observational study will be a documentation of the prescribing and administration practices of Enbrel® and their impact on ankylosing spondylitis patients outcome in a real life setting.
- Trial name
- NCT01188655
- Testing
- Enbrel
- Volunteers
- 89 people
- Sponsor
- Pfizer
Ankylosing Spondylitis
A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis
The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared to certolizumab pegol in the treatment of subjects with active ankylosing spondylitis (AS).
- Trial name
- NCT03215277
- Testing
- Bimekizumab, Certolizumab pegol
- Where
- 34 sites in United States, Czechia and 6 more
- Volunteers
- 76 people
- Sponsor
- UCB Biopharma SRL
Ankylosing Spondylitis
Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis
The primary objective of this study is to evaluate the efficacy of safety of etanercept dose reduction combined with sulfasalazine in ankylosing spondylitis (AS) patients who have achieved a significant clinical response.
- Trial name
- NCT02638896
- Testing
- etanercept (Half-Dose), etanercept (Full-Dose), Sulfasalazine
- Volunteers
- 100 people
- Sponsor
- Zhixiang Huang
Ankylosing Spondylitis
Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)
This study of adalimumab (Humira) will be conducted to clarify the following with regard to the treatment of ankylosing spondylitis with this drug: Unknown adverse drug reactions (especially important adverse drug reactions)…
- Trial name
- NCT01329380
- Where
- 194 sites in Japan
- Volunteers
- 403 people
- Sponsor
- AbbVie
Ankylosing Spondylitis
Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
This is an observational study to evaluate the effectiveness and safety of secukinumab in participants with AS who have never used TNFi, JAKi, or IL-17i drugs before.
- Trial name
- ONSET (NCT06905288)
- Testing
- Secukinumab
- Where
- 3 sites in South Korea
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Ankylosing Spondylitis
NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis
To evaluate the impact of treatment with a non-steroidal anti-inflammatory drug (NSAID) - Celecoxib - when added to anti-tumour necrosis factor (TNF) therapy - Golimumab - as compared to anti-TNF therapy (Golimumab) alone on…
- Trial name
- CONSUL (NCT02758782)
- Testing
- Golimumab, Celecoxib
- Where
- 19 sites in Germany
- Volunteers
- 156 people
- Sponsor
- Charite University, Berlin, Germany
Sarcoidosis, Tuberculosis
The Serum Angiotensin Converting Enzyme and Lysozyme Levels in Patients Non-infectious and Infectious Uveitis
This study evaluates the significance of differences in serum angiotensin converting enzyme and lysozyme levels of patients with ocular involvement of other autoimmune inflammatory and infectious diseases.
- Trial name
- uveitis (NCT02627209)
- Testing
- spectrophotometric assay, radial immunodiffusion
- Where
- Turkey (Türkiye)
- Volunteers
- 280 people
- Sponsor
- Ozlem Sahin
Axial Spondylarthritis (axSpA)
Initial Standardized Global Review in Axial Spondyloarthritis
This study will be a pragmatic, cluster-randomized, controlled study with two parallel arms ( 'intervention' and 'usual care' (UC) arms) of one year duration.
- Trial name
- REVINSPA (NCT07141017)
- Testing
- Initial standardized global review
- Where
- 21 sites in France
- Volunteers
- 154 people
- Sponsor
- Association de Recherche Clinique en Rhumatologie
Crohn Disease, Ulcerative Colitis
National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life
National, prospective, multicentre observational study designed for eligible patients treated with Inflectra. Its objectives are to describe under real conditions of use, the profile of patients treated with Inflectra and the…
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- ReFLECT (NCT02925338)
- Testing
- QOL questionaire
- Where
- 67 sites in France
- Volunteers
- 1,431 people
- Sponsor
- Pfizer
Spondylitis, Ankylosing Spondylitis
Genetics of Ankylosing Spondylitis
Ankylosing spondylitis (AS) is a chronic inflammatory disease that affects the joints between the vertebrae of the spine and the joints between the spine and the pelvis.
- Trial name
- NCT00081562
- Where
- 2 sites in United States
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Ankylosing Spondylitis
Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA
The purpose of this global study was to demonstrate the efficacy, safety, and tolerability of an intravenous (i.v.) regimen of secukinumab compared to placebo in participants with active ankylosing spondylitis (AS) or…
- Trial name
- NCT04156620
- Testing
- Secukinumab
- Where
- 102 sites in United States, Belgium and 16 more
- Volunteers
- 527 people
- Sponsor
- Novartis Pharmaceuticals